Rigel commences R343 and R333 Phase 2 studies in allergic asthma, discoid lupus erythematosus

NewsGuard 100/100 Score
Editorial Checklist Reviewed
Sep 6 2012Rigel Pharmaceuticals, Inc.
Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that it has commenced Phase 2 clinical studies with two of the company's most advanced proprietary therapeutic product candidates. R343 is an inhaled SYK inhibitor that is being evaluated as a potential treatment for allergic asthma. R333 is a topical JAK/SYK inhibitor aimed at treating various phases of discoid lupus erythematosus (DLE, or lupus of the skin). 

"R343 and R333 are leading the way in a substantial lineup of proprietary product candidates in Rigel's pipeline," said James M. Gower, chairman and chief executive officer of Rigel.  "In addition to fostamatinib, which is in Phase 3 with our partner AstraZeneca, we now have two products in Phase 2 clinical studies and several more in, or preparing to enter, the clinic. Rigel continues to demonstrate its R&D productivity," he added.

Source:

Rigel Pharmaceuticals, Inc.

Posted in: Drug Trial News | Medical Condition News

Tags: , , , , , , , , , , , , , , ,

Comments (0)

Suggested Reading

Newly discovered cause for asthma sparks hope for treatment
SARS-COV-2 infection not linked to increased risk of asthma development in pediatric patients
Air pollution in Austin neighborhoods raises asthma-related ER visits, study finds
Understanding the unique types and triggers of asthma
Plant-based diets trigger remission in Sjögren's syndrome and lupus cases
Second-hand vape smoke linked to more asthma symptoms in kids
Research confirms no association between SARS-CoV-2 and childhood asthma diagnoses
Early exposure to air pollution tied to higher childhood asthma risk, disparities worsen impact

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
(Logout)
Post

Newsletters you may be interested in

See all Newsletters »

Terms

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

Provide Feedback

You might also like...
Innovative study on asthma inflammation funded by NIH/NIAID grant